Categories Earnings, Health Care

Infographic: Biogen (BIIB) Q1 2020 Earnings Results

Biogen Inc. (NASDAQ: BIIB) reported its financial results for the quarter ended March 31, 2020 today.

Biogen posted a 1% decline in earnings for the first quarter of 2020 due to higher costs and expenses despite a 1% rise in the top-line. The company continued to develop and expand its pipeline, including making good progress toward the US regulatory filing for aducanumab, as well as bolstering its efforts in gene therapy through a collaboration with Sangamo.

Biogen (BIIB) Q1 2020 earnings review

The company believes that the magnitude and uncertainty surrounding the COVID-19 pandemic clearly introduce unanticipated and potentially unquantifiable risks to its business and results over the near-term. While Biogen does expect there will be some impact on timelines for certain of its clinical programs, it still expects the vast majority of the 10 remaining near-term readouts to occur before the end of 2021.

Past Performance

Most Popular

Important takeaways from Conagra Brands’ Q4 2025 report

Conagra Brands, Inc. (NYSE: CAG), a leading provider of consumer packaged goods, reported weaker-than-expected sales and adjusted earnings for its fourth quarter, reflecting ongoing economic uncertainty and muted consumer spending.

Delta Air Lines (DAL) gains on strong Q2 2025 performance

Shares of Delta Air Lines (NYSE: DAL) rose 12% on Thursday after the company delivered strong results for the second quarter of 2025 and restored its guidance for the full

CAG Earnings: Conagra Brands Q4 adj. profit drops, misses estimates

Conagra Brands, Inc. (NYSE: CAG), a leading provider of consumer packaged goods, reported lower sales and adjusted earnings for the fourth quarter of 2025. Results missed analysts' estimates. Net sales

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top